echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > 4 plus 7 pilot set to pick "directed blasting" explosion to people?

    4 plus 7 pilot set to pick "directed blasting" explosion to people?

    • Last Update: 2020-07-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    TextsLatte cat4 plus 7 belt volume procurement is the original intention is to let ordinary people use low-cost high-quality drugsCollective price reduction, not only on the profits of enterprises have a "abyss impact", but also subverted the previous competition model, changed the market environment, sales and promotion of the space continues to squeeze, can be said to be for expired patent drugs high-priced drugs for "targeted blasting."With the new collection policy is advancing step by step, looking back, 2018 the first batch of 4 plus 7 pilot collection - high-priced drugs directed blast explosion? How was the original drug going? What about the winning company? Do other businesses have breathing room?in the Ameida Sample Public Hospital Database, 11 cities in the 2018-2019 collection range, the lipid-lowering drugs Atovastatin and Rishuavastatin, the winning companies showed a decline in sales and sales blowout, market share has been somewhat increasedThe rise of the share is more like a "good card", except the name, everything is not goodHowever, while the sales of Pfizer and AstraZeno's original drugs are on a downward trend, the decline is not particularly large compared to domestic generics, and still holds a steady majority of the market shareOn the contrary, sales and sales of other domestic generics have fallen sharply, and the market share has narrowed"Directed blasting" the original research drug, it does not seem so smooth..Anti-hepatitis B drug Entikave's winning bid company Zhengda Pharmaceuticals also showed a sales blowout situationBut it's worth noting that while sales at the sample hospital, Entikawe, a pharmaceutical company, have grown sharply, they have not been able to withstand a sharp decline in sales and market sharePrices have fallen too much, and the increase in sales has not resisted the declineAt the same time, sales and sales of other generic selling companies also fell sharply, and market share narrowedOn the other hand, the market share of the original research drug of The mesusco-Squibb has increased significantly, even leaping to about 60% of the market, with sales down 31.87 percent and sales down only 17.2 percent, very strongAnd for other domestic generic drugs, Wan Wan did not expect you to be such a "directed blasting"In pharmacies, the majority of Zhengda Pharmaceuticals and Baishi Mei shiguibao were basically flat, other enterprises slightly increased market share Nowadays, with the low-cost effect of the implementation of the 4 plus 7, coupled with medical insurance reimbursement, a large number of drug buyers from pharmacies into the hospital There was a significant decline in the number of customer orders from sample drugstore chains in 2019 for the variety of the volume of procurement, physical pharmacies or do not struggle, with the change of user group, purchase habits, offline pharmacies and online platform linkage and other factors, physical pharmacies may be more to explore the online pharmacy model, the latter is a good development trend Although its adjustment effect is limited, it is unlikely to crowd out a large market share of hospitals at present, but the impact on ordinary social pharmacies is very obvious Ordinary pharmacies are also facing a crisis, will inevitably usher in the transformation of business model and enterprise linkage the cardiovascular drug clopidogrel was similar, the market share of the original species was little affected, while Lepu fell dramatically From the results, the equivalent is the winning enterprise crowded out other enterprises, and did not affect the original research drug Later, in September 2019, Xinlitai lost its bid in the second batch of collections, with Stone Pharmaceutical Group, Sanofi and Lepp winning the bid, and the play behind it was even more exciting Lost Tyjia's letter Litai, what other king can be used? Sichuan Huiyu was greatly affected by the purchase of 4 plus 7 bands, in line with the policy expectations Its anti-cancer injection sedative Semequese quickly grabbed about 1/3 of the market share, leading enterprises Jiangsu Hausen, Qilu Pharmaceutical market share fell, most of the outstanding enterprises sales and sales have declined significantly Perhaps due to strong marketing capabilities, Fosun Pharma has seen a sharp increase in sales and sales under the collection policy Even with a large share of the original share of the enterprise after winning the bid, the market still has some room for prepared unwinning enterprises thus, in the market game of the collection policy, not only to consider the use of channels and production processes of large enterprises to fight price war, but also to be wary of small-scale enterprises through sharp price reductions to quickly squeeze into the market similarly, , the winning bid of chloratan zhejiang Huahai sales and sales blowout, one to seize about 25% of the market share However, Mercadong's original research drugs still fell by little, to Yangzijiang-led domestic generic drugs were hit hard, the volume of prices have fallen, the original market was not very strong squeeze Into the collection of blood, did not enter the collection to collect tears, this is probably the most intuitive feeling of many pharmaceutical companies on the whole, the first batch of collection on the original research drug has a certain impact, although the original research drug prices fell, but still occupy a huge market share The strength is not great, the effect is limited On the one hand, it is the accumulation of market cultivation and long-term publicity and promotion made by foreign-funded enterprises, patients have a strong dependence on the original research drug, on the other hand, from the sample public hospital data, there is the possibility of water in hospital reporting in the first batch of collection, not winning the bid of several domestic generic drug leading enterprises suffered a greater degree of frustration Some small and medium-sized enterprises in the development and rising stage, either with the help of volume procurement suddenly turned around, or by the impact of low prices are further weakened the embarrassment of the failed pharmaceutical companies is also that if there is not a volume-for-price show sufficient cooperation sincerity, and ultimately still face the market of price reduction competition the first batch of "directional blasting" although has achieved some results, but has not yet achieved the goal With the follow third batch of collection, will certainly experience the storm of enterprises to start a new round of game It is hoped that the collection of domestic hit down, the original research is still strong, otherwise, the goal of national security strategy, to achieve some difficulties.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.